valsartan has been researched along with Proteinuria in 63 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (3.17) | 18.2507 |
| 2000's | 27 (42.86) | 29.6817 |
| 2010's | 29 (46.03) | 24.3611 |
| 2020's | 5 (7.94) | 2.80 |
| Authors | Studies |
|---|---|
| Bo, W; Li, L; Peng, Z; Xiaowei, L | 1 |
| Bo, W; Chen, H; Hongbao, L; Li, L; Peng, Z; XiaoWei, L; Xiong, C | 1 |
| Imanishi, M; Kobara, H; Konishi, Y; Masaki, T; Morikawa, T; Nakano, D; Nishiyama, A; Rafiq, K; Rahman, A; Sherajee, SJ | 1 |
| Huh, W; Jang, HR; Jeon, J; Kim, DH; Kim, DJ; Kim, HY; Kim, YG; Lee, JE | 1 |
| Chen, G; Chen, L; Li, X; Wen, Y; Ye, W; Zhou, Y; Zou, L | 1 |
| Asada, N; Awazu, M; Furuhata, M; Hashiguchi, A; Matsuoka, D; Naganuma, K; Noda, S; Tsukahara, T | 1 |
| Barbera, V; Bellasi, A; Cozzolino, M; De Pascalis, A; Di Lullo, L; Floccari, F; Mudoni, A; Rivera, R; Ronco, C; Santoro, A; Verdesca, S | 1 |
| Chin, HJ; Kim, YC; Koo, HS; Yu, MY | 1 |
| Abdel Kawy, HS | 1 |
| Chen, C; Gan, L; Li, X; Luo, H; Zhou, Q; Zhu, M | 1 |
| Bianchi, F; Cotugno, M; Forte, M; Madonna, M; Marchitti, S; Rubattu, S; Stanzione, R; Volpe, M | 1 |
| Antonio, ZL; Glazer, RD; Kang, HG; Lou-Meda, R; Stiller, B; Tan, M; Valentin, MA; Wang, L; Yap, HK; Zielinska, E | 1 |
| Aroor, AR; Chandrasekar, B; Das, NA; DeMarco, VG; Habibi, J; Hayden, MR; Johnson, MS; Manrique-Acevedo, CM; Nistala, R; Wiedmeyer, C | 1 |
| Howard, A; Kopp, JB; Levi, M; Li, C; Qiu, L; Solis, N; Wang, W; Wang, X | 1 |
| Baigent, C; Haynes, R; Judge, P; Landray, MJ | 1 |
| Chen, F; Cheng, G; Fang, Y; Guo, Y; Li, H; Liu, D; Liu, F; Liu, L; Liu, Z; Margetts, P; Tang, L; Zhao, Z | 1 |
| Chen, J; Hu, YJ; Peng, DF; Tang, SY | 1 |
| Alpa, M; Cravedi, P; Daina, E; Gamba, S; Gaspari, F; Perna, A; Remuzzi, G; Roccatello, D; Ruggenenti, P | 1 |
| Atanasovska, E; Cekovska, S; Gjorgjievska, K; Jurhar-Pavlova, M; Pavlovska, K; Zafirov, D; Zendelovska, D | 1 |
| Kimura, K; Shibagaki, Y; Uehara, K; Yasuda, T | 1 |
| Cao, YM; Gao, WH; Hu, JW; Lv, YB; Mu, JJ; Wang, Y; Xie, BQ; Yan, DY; Yuan, ZY; Zheng, WL | 1 |
| Choi, HY; Han, SW; Jo, YI; Kie, JH; Lee, SH; Lee, YK; Lim, SD; Moon, JY; Na, HY; Park, HC; Shin, SK; Yang, DH | 1 |
| Faedda, R; Loriga, G; Ruggenenti, P; Sanna, M; Satta, AE; Vidili, G | 1 |
| Chen, JS; Cheng, DR; Cheng, Z; Ji, SM; Li, LS; Liu, ZH; Sha, GZ; Wen, JQ | 1 |
| Chang, NC; Lee, TM | 1 |
| Chihara, K; Dan, T; Izuhara, Y; Kurokawa, K; Miyata, T; Ohtomo, S; Robert, A; Tominaga, N; Van Ypersele de Strihou, C | 1 |
| Anand, IS; Bishu, K; Cohn, JN; Ishani, A; Kuskowski, MA; Rector, TS | 1 |
| Ekhlas, A; Esnault, VL; Moranne, O; Nguyen, JM | 1 |
| Hu, Z; Jiang, B; Li, X; Peng, T; Xia, Q; Yang, X | 1 |
| Guo, L; Hu, Z; Jiang, B; Li, XH; Pei, F; Peng, T; Song, J; Xia, Q; Yang, XD | 1 |
| Battaglia, G; Cambareri, F; Carminati, S; Cravedi, P; David, S; Ene-Iordache, B; Gaspari, F; Granata, A; Ledda, F; Loriga, G; Motterlini, N; Perna, A; Remuzzi, G; Rota, S; Rubis, N; Ruggenenti, P; Satta, A; Stucchi, N; Tonelli, M | 1 |
| Kamide, K; Maekawa, Y; Ohishi, M; Onishi, M; Rakugi, H; Takeya, Y; Tatara, Y; Yamamoto, K | 1 |
| Chae, DW; Do, JY; Huh, W; Jang, HR; Kim, DJ; Kim, SG; Kim, YG; Lee, JE; Lee, YJ; Oh, HY | 1 |
| Hemmelder, MH; Janssen, WM; Lambers Heerspink, HJ; Laverman, GD; Navis, G; Slagman, MC; Waanders, F; Woittiez, AJ | 1 |
| Chen, H; Li, H; Liu, Z; Tang, L; Yang, B; Yi, R | 1 |
| Bilić, M; Galesić, K; Horvatić, I; Ljubanović, D; Munjas-Samarin, R | 1 |
| Aritomi, S; Konda, T; Niinuma, K; Nitta, K; Ogawa, T | 1 |
| Endoh, M; Ideura, T; Kamata, K; Kimura, K; Suzuki, D; Tamura, K; Toya, Y; Umemura, S; Yasuda, T; Yoshimura, A | 1 |
| Border, WA; Cheung, AK; Gu, C; Huang, Y; Noble, NA; Zhou, G | 1 |
| Dikkeschei, BD; Dullaart, RP; Kwakernaak, AJ; Lambert, G; Laverman, GD; Navis, G; Petrides, F; Slagman, MC; Waanders, F | 1 |
| Benigni, A; Donadoni, C; Fassi, A; Gagliardini, E; Lepre, MS; Remuzzi, A; Remuzzi, G; Sangalli, F | 1 |
| Aros, C; Bertocchi, F; Campbell, R; Fagiani, L; Perna, A; Perticucci, E; Remuzzi, A; Remuzzi, G; Ruggenenti, P; Sangalli, F; Viscarra, C | 1 |
| Campo, C; Praga, M; Rodicio, JL; Ruilope, LM; Segura, J | 1 |
| Abe, Y; Fukui, T; Hitomi, H; Kimura, S; Kiyomoto, H; Kobori, H; Kohno, M; Nishiyama, A; Rahman, M; Shokoji, T; Yao, L; Zhang, GX | 1 |
| He, SX; Ling, HX; Sun, SY | 1 |
| Hollomby, DJ; House, A; Jevnikar, AM; Muirhead, N | 1 |
| Kanno, Y; Nakamoto, H; Okada, H; Sugahara, S; Suzuki, H | 1 |
| Banfi, C; Brioschi, M; Crippa, V; de Gasparo, M; Gelosa, P; Gianazza, E; Gianella, A; Guerrini, U; Nobili, E; Sironi, L; Tremoli, E | 1 |
| Chihara, Y; Fujimori, T; Iidaka, K; Inada, H; Ishimitsu, T; Matsuoka, H; Ogihara, T; Ono, H; Ono, Y; Rakugi, H; Ueda, Y | 1 |
| Delcroix, C; Ekhlas, A; Esnault, VL; Moutel, MG; Nguyen, JM | 1 |
| Adani, GL; Baccarani, U; Boscutti, G; Bresadola, F; Gropuzzo, M; Mioni, G; Mioni, R; Montanaro, D; Risaliti, A; Sainz, M; Tulissi, P; Vallone, C | 1 |
| Iigaya, K; Kumagai, H; Onami, T; Saruta, T; Takimoto, C | 1 |
| Akashiba, A; Ando, N; Inada, H; Ishimitsu, T; Kameda, T; Matsuoka, H; Minami, J; Ohta, S; Ono, H; Takahashi, T; Tsukada, K; Yoshii, M | 1 |
| Chen, N; Hao, L; Sun, G; Wang, W; Wu, K; Zhang, Y; Zhou, T | 1 |
| Acikel, C; Caglar, K; Cakir, E; Eyileten, T; Kurt, Y; Oguz, Y; Saglam, M; Sonmez, A; Tasar, M; Vural, A; Yenicesu, M; Yilmaz, MI | 1 |
| Chen, WD; Huang, YY; Li, LH; Wang, YW; Xu, HH; Yang, LC; Yang, YL; Zhang, DY; Zhu, XJ | 1 |
| Hayashi, N; Ito, N; Iwamoto, Y; Katsuya, T; Ogihara, T; Ohishi, M; Rakugi, H; Shiota, A; Takagi, T; Tatara, Y | 1 |
| Böger, RH; Galle, J; Pinnetti, S; Schwedhelm, E; Wanner, C | 1 |
| Barclay, BW; Navarrete, AE; Sahota, P; Webb, RL; Wosu, NJ | 1 |
| Bünten, B; Grabensee, B; Németh, R; Plum, J | 1 |
| Aldigier, JC; Botteri, F; Mann, JF; Oddou-Stock, P; Ponticelli, C; Ruilope, LM | 1 |
| Kozlovskaia, NL; Medvedeva, TIu; Miroshnichenko, NG; Okonova, EB; Plieva, OK; Rudenko, TE; Shonichev, DG; Shvetsov, MIu; Stavrovskaia, EV | 1 |
3 review(s) available for valsartan and Proteinuria
| Article | Year |
|---|---|
[Neprilysin inhibition and chronic kidney disease].
Topics: Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Disease Progression; Diuresis; Drug Combinations; Heart Failure; Humans; Hypertension; Kidney Failure, Chronic; Models, Biological; Molecular Targeted Therapy; Natriuresis; Natriuretic Peptides; Neprilysin; Proteinuria; Renal Insufficiency, Chronic; Renin-Angiotensin System; Tetrazoles; Valsartan | 2017 |
Neprilysin inhibition in chronic kidney disease.
Topics: Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Disease Progression; Drug Combinations; Heart Failure; Humans; Hypertension; Kidney Failure, Chronic; Natriuresis; Nephrology; Neprilysin; Proteinuria; Pyridines; Renin-Angiotensin System; Tetrazoles; Thiazepines; Treatment Outcome; Valsartan | 2015 |
[Molecular mechanisms underlying proteinuria reduction and protection of nephrin and podocytes by ARB].
Topics: Actinin; Actins; Adaptor Proteins, Signal Transducing; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Cytoskeletal Proteins; Humans; Intracellular Signaling Peptides and Proteins; Kidney Failure, Chronic; Membrane Proteins; Podocytes; Proteins; Proteinuria; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan | 2006 |
34 trial(s) available for valsartan and Proteinuria
| Article | Year |
|---|---|
Comparison of the effects of valsartan plus activated vitamin D versus valsartan alone in IgA nephropathy with moderate proteinuria.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glomerulonephritis, IGA; Humans; Male; Middle Aged; Prospective Studies; Proteinuria; Valsartan; Vitamin D; Vitamins; Young Adult | 2020 |
Evaluation of the efficacy and safety of TWHF in diabetic nephropathy patients with overt proteinuria and normal eGFR.
Topics: Adult; Aged; Antihypertensive Agents; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Phytotherapy; Plant Extracts; Proteinuria; Renin-Angiotensin System; Treatment Outcome; Tripterygium; Valsartan | 2020 |
Short-term anti-proteinuric effect of tacrolimus is not related to preservation of the glomerular filtration rate in IgA nephropathy: A 5-year follow-up study.
Topics: Adult; Antihypertensive Agents; Captopril; Creatinine; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Glomerular Filtration Rate; Glomerulonephritis, IGA; Humans; Immunosuppressive Agents; Male; Middle Aged; Proteinuria; Renin-Angiotensin System; Tacrolimus; Treatment Outcome; Valsartan | 2017 |
Acteoside relieves mesangial cell injury by regulating Th22 cell chemotaxis and proliferation in IgA nephropathy.
Topics: Adult; Biopsy; Cell Line; Cell Proliferation; Chemokine CCL20; Chemokine CCL22; Chemokine CCL27; Chemotaxis; Coculture Techniques; Disease Progression; Drug Therapy, Combination; Female; Glomerulonephritis, IGA; Glucosides; Humans; Immunosuppressive Agents; Male; Mesangial Cells; Middle Aged; Phenols; Proteinuria; Rehmannia; T-Lymphocytes, Helper-Inducer; Transforming Growth Factor beta1; Treatment Outcome; Valsartan; Young Adult | 2018 |
Long-term safety and tolerability of valsartan in children aged 6 to 17 years with hypertension.
Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Child; Cough; Creatinine; Drug Therapy, Combination; Female; Fever; Glomerular Filtration Rate; Headache; Humans; Hypertension; Male; Nasopharyngitis; Prospective Studies; Proteinuria; Renal Insufficiency, Chronic; Serum Albumin, Human; Severity of Illness Index; Time Factors; Treatment Outcome; Valsartan | 2019 |
Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Biomarkers; China; Clopidogrel; Creatinine; Disease Progression; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glomerulonephritis, IGA; Humans; Immunosuppressive Agents; Isoxazoles; Kidney; Leflunomide; Male; Platelet Aggregation Inhibitors; Proteinuria; Tetrazoles; Ticlopidine; Time Factors; Treatment Outcome; Valine; Valsartan | 2015 |
Estimated Glomerular Filtration Rate Variability Independently Predicts Renal Prognosis in Advanced Chronic Kidney Disease Patients.
Topics: Age Factors; Aged; Angiotensin II Type 1 Receptor Blockers; Endpoint Determination; Female; Glomerular Filtration Rate; Humans; Hypertension, Renal; Male; Middle Aged; Predictive Value of Tests; Prognosis; Proteinuria; Renal Insufficiency, Chronic; Reproducibility of Results; Sex Factors; Valsartan | 2015 |
Effect of low-dose valsartan on proteinuria in normotensive immunoglobulin A nephropathy with minimal proteinuria: a randomized trial.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; Creatinine; Female; Glomerulonephritis, IGA; Humans; Male; Middle Aged; Prospective Studies; Proteinuria; Republic of Korea; Time Factors; Treatment Outcome; Valsartan | 2016 |
Renal hemodynamics and renoprotection.
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Female; Humans; Hypertension, Renal; Male; Middle Aged; Proteinuria; Renal Circulation; Renin; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2008 |
Therapeutic effect of Tripterygium wilfordii on proteinuria associated with sirolimus in renal transplant recipients.
Topics: Adult; Antihypertensive Agents; China; Female; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Mycophenolic Acid; Plant Extracts; Proteinuria; Sirolimus; Tetrazoles; Tripterygium; Valine; Valsartan; Young Adult | 2008 |
Effect of nicorandil on proteinuria in well controlled hypertensive patients.
Topics: Aged; Antihypertensive Agents; Case-Control Studies; Creatinine; Diuretics, Osmotic; Double-Blind Method; Endothelin-1; Female; Humans; Isosorbide; Male; Middle Aged; Nicorandil; Prospective Studies; Proteinuria; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2009 |
Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Heart Failure; Humans; Kidney Diseases; Male; Middle Aged; Proteinuria; Severity of Illness Index; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2009 |
Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Chronic Disease; Diuretics; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Humans; Kidney Diseases; Male; Middle Aged; Proteinuria; Ramipril; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2010 |
A comparative study of the renoprotective effects of benidipine and valsartan in primary hypertensive patients with proteinuria.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Female; Glomerular Filtration Rate; Humans; Hypertension; Kidney Diseases; Male; Middle Aged; Proteinuria; Renal Circulation; Tetrazoles; Valine; Valsartan | 2009 |
[Renal protective effects of benidipine and valsartan in primary hypertension patients with proteinuria].
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Calcium Channel Blockers; Dihydropyridines; Female; Glomerular Filtration Rate; Humans; Hypertension; Male; Middle Aged; Proteinuria; Tetrazoles; Valine; Valsartan | 2010 |
Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Blood Pressure; Chi-Square Distribution; Chronic Disease; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Italy; Kidney Diseases; Lipids; Male; Middle Aged; Prospective Studies; Proteinuria; Renin-Angiotensin System; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2010 |
Strong suppression of the renin-angiotensin system has a renal-protective effect in hypertensive patients: high-dose ARB with ACE inhibitor (Hawaii) study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Chronic Disease; Drug Therapy, Combination; Female; Hawaii; Humans; Hypertension; Imidazoles; Imidazolidines; Kidney; Kidney Diseases; Male; Middle Aged; Proteinuria; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2010 |
Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Chronic Disease; Combined Modality Therapy; Cross-Over Studies; Diet, Sodium-Restricted; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Kidney Diseases; Lisinopril; Male; Middle Aged; Patient Compliance; Proteinuria; Sodium Chloride, Dietary; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2011 |
Effects of ramipril and valsartan on proteinuria and renal function in patients with nondiabetic proteinuria.
Topics: Adult; Aged; Angiotensin II Type 2 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Creatinine; Humans; Kidney; Middle Aged; Prospective Studies; Proteinuria; Ramipril; Tetrazoles; Valine; Valsartan | 2011 |
Effects of valsartan on progression of kidney disease in Japanese hypertensive patients with advanced, predialysis, chronic kidney disease: Kanagawa Valsartan Trial (KVT).
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Asian People; Blood Pressure; Comorbidity; Creatinine; Disease Progression; Female; Humans; Hypertension; Japan; Male; Middle Aged; Proteinuria; Renal Insufficiency, Chronic; Renal Replacement Therapy; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: relationship with lipoprotein response to antiproteinuric treatment.
Topics: Adult; Diet, Sodium-Restricted; Female; Humans; Lipoproteins; Lisinopril; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Proteinuria; Serine Endopeptidases; Tetrazoles; Valine; Valsartan | 2013 |
Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies.
Topics: Adult; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Chronic Disease; Cross-Over Studies; Dextrans; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glomerulonephritis, IGA; Humans; Male; Middle Aged; Prospective Studies; Proteinuria; Renal Circulation; Tetrazoles; Valine; Valsartan | 2003 |
Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Drug Therapy, Combination; Female; Humans; Kidney Diseases; Male; Middle Aged; Pilot Projects; Proteinuria; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2003 |
[Clinical observation of the therapeutic effect of valsartan for renal hypertension in 64 cases].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Urea Nitrogen; Creatinine; Electrolytes; Humans; Hypertension, Renal; Middle Aged; Proteinuria; Tetrazoles; Valine; Valsartan | 2003 |
Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Creatinine; Female; Humans; Hypertension; Japan; Kidney; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Cavity; Peritoneal Dialysis, Continuous Ambulatory; Prospective Studies; Proteinuria; Retrospective Studies; Tetrazoles; Urine; Valine; Valsartan | 2004 |
Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents.
Topics: Adult; Aged; Antihypertensive Agents; Cross-Over Studies; Diet, Sodium-Restricted; Diuretics; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Kidney Failure, Chronic; Kidney Function Tests; Male; Middle Aged; Prospective Studies; Proteinuria; Ramipril; Reference Values; Risk Assessment; Severity of Illness Index; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2005 |
Renoprotective effect of early inhibition of the renin-angiotensin system in renal transplant recipients.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Creatinine; Enalapril; Follow-Up Studies; Humans; Hypertension; Kidney Function Tests; Kidney Transplantation; Losartan; Proteinuria; Ramipril; Renal Artery; Renin-Angiotensin System; Tetrazoles; Time Factors; Valine; Valsartan | 2005 |
Effects of valsartan on the progression of chronic renal insufficiency in patients with nondiabetic renal diseases.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cross-Over Studies; Female; Glomerulonephritis; Humans; Middle Aged; Nephrosclerosis; Proteinuria; Renal Insufficiency, Chronic; Tetrazoles; Valine; Valsartan | 2005 |
Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril versus valsartan.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Arginine; Biomarkers; Blood Glucose; C-Reactive Protein; Female; Glomerular Filtration Rate; Hemorheology; Humans; Insulin Resistance; Kidney Failure, Chronic; Lipids; Male; Middle Aged; Proteinuria; Ramipril; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan; Vasodilation | 2007 |
Renal protective effect in hypertensive patients: the high doses of angiotensin II receptor blocker (HARB) study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Dose-Response Relationship, Drug; Female; Heart Rate; Humans; Hypertension; Kidney; Male; Middle Aged; Proteinuria; Tetrazoles; Valine; Valsartan | 2007 |
Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Arginine; Benzimidazoles; Benzoates; Blood Pressure; C-Reactive Protein; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dinoprost; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Proteinuria; Renin-Angiotensin System; Telmisartan; Tetrazoles; Valine; Valsartan | 2008 |
Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension.
Topics: Aged; Albuminuria; Angiotensin II; Antihypertensive Agents; Blood Pressure; Blood Urea Nitrogen; Creatinine; Dextrans; Double-Blind Method; Erythrocyte Count; Female; Glomerular Filtration Rate; Humans; Hypertension, Renal; Inulin; Kidney Failure, Chronic; Kidney Glomerulus; Male; Middle Aged; Molecular Weight; p-Aminohippuric Acid; Particle Size; Potassium; Prospective Studies; Proteinuria; Renal Circulation; Tetrazoles; Valine; Valsartan | 1998 |
Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Blood Pressure; Creatinine; Drug Combinations; Female; Humans; Hypertension; Kidney Failure, Chronic; Male; Middle Aged; Pilot Projects; Potassium; Proteinuria; Safety; Tetrazoles; Valine; Valsartan | 2000 |
[Experience in the use of valsartan with the aim to inhibit progression of kidney failure in patients with chronic glomerulonephritis].
Topics: Adult; Antihypertensive Agents; Chronic Disease; Female; Follow-Up Studies; Glomerulonephritis; Humans; Hypertension; Kidney Failure, Chronic; Kidney Function Tests; Male; Middle Aged; Proteinuria; Tetrazoles; Time Factors; Valine; Valsartan | 2001 |
26 other study(ies) available for valsartan and Proteinuria
| Article | Year |
|---|---|
The angiotensin II receptor-neprilysin inhibitor LCZ696 attenuates the progression of proteinuria in type 2 diabetic rats.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Diabetes Mellitus, Type 2; Drug Combinations; Proteinuria; Rats; Rats, Inbred OLETF; Tetrazoles; Valsartan | 2020 |
Urinary angiotensinogen as a surrogate marker predicting the antiproteinuric effects of angiotensin receptor blockers in patients with overt proteinuria: a multicenter prospective study.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Female; Humans; Male; Middle Aged; Prognosis; Prospective Studies; Proteinuria; Renal Insufficiency, Chronic; Treatment Outcome; Valsartan | 2020 |
Continuous hypergammaglobulinemia and proteinuria after the recovery of the visceral Leishmaniasis: a case report.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Humans; Hypergammaglobulinemia; Kidney; Leishmaniasis, Visceral; Male; Proteinuria; Treatment Outcome; Valsartan | 2021 |
Polycythemia, capillary rarefaction, and focal glomerulosclerosis in two adolescents born extremely low birth weight and premature.
Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Antigens, CD34; Apgar Score; Biopsy; Child; Endothelial Cells; Erythropoietin; Female; Fibrosis; Glomerulosclerosis, Focal Segmental; Hemoglobins; Humans; Infant, Extremely Premature; Infant, Newborn; Infant, Premature, Diseases; Infant, Very Low Birth Weight; Kidney Glomerulus; Kidney Tubules; Male; Microvascular Rarefaction; Nephrons; Platelet Endothelial Cell Adhesion Molecule-1; Polycythemia; Pregnancy; Premature Birth; Proteinuria; Valsartan | 2017 |
Aliskiren and valsartan in combination is a promising therapy for hypertensive renal injury in rats.
Topics: Amides; Animals; Antihypertensive Agents; Blood Pressure; Blood Urea Nitrogen; Creatinine; Drug Therapy, Combination; Enzyme Inhibitors; Fumarates; Hypertension; Kidney; Kidney Diseases; Male; NG-Nitroarginine Methyl Ester; Oxidative Stress; Proteinuria; Rats; Rats, Wistar; Valsartan | 2018 |
Effects of dual angiotensin type 1 receptor/neprilysin inhibition vs. angiotensin type 1 receptor inhibition on target organ injury in the stroke-prone spontaneously hypertensive rat.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Biphenyl Compounds; Blood Pressure; Cyclic GMP; Drug Combinations; Hypertension; Male; Neprilysin; Proteinuria; Rats; Rats, Inbred SHR; Stroke; Tetrazoles; Valsartan | 2018 |
The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Arterial Pressure; Biomarkers; Biphenyl Compounds; Blood Glucose; Diabetic Nephropathies; Disease Models, Animal; Drug Combinations; Fibrosis; Kidney Glomerulus; Kidney Tubules; Lipids; Male; Neprilysin; Nitrosative Stress; Oxidative Stress; Protease Inhibitors; Proteinuria; Rats, Zucker; Tetrazoles; Time Factors; Valsartan | 2019 |
Protective effects of aliskiren and valsartan in mice with diabetic nephropathy.
Topics: Albumins; Amides; Animals; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Endoplasmic Reticulum Stress; Fumarates; Inflammation; Lipid Metabolism; Male; Membrane Proteins; Mesangial Cells; Mice, Inbred DBA; Podocytes; Protective Agents; Proteinuria; Proto-Oncogene Mas; Proto-Oncogene Proteins; Receptors, G-Protein-Coupled; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2014 |
Protective effects of valsartan and benazepril combined with atorvastatin on cardiorenal syndrome in rats.
Topics: Angiotensin II; Animals; Atorvastatin; Benzazepines; C-Reactive Protein; Cardio-Renal Syndrome; Case-Control Studies; Drug Synergism; Heptanoic Acids; Lipids; Male; Natriuretic Peptide, Brain; Proteinuria; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2015 |
A multidrug, antiproteinuric approach to alport syndrome: a ten-year cohort study.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Calcium Channel Blockers; Cohort Studies; Diltiazem; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Kidney Function Tests; Male; Middle Aged; Nephritis, Hereditary; Prospective Studies; Proteinuria; Valsartan | 2015 |
Protective effects of AT1-receptor blocker and CA antagonist combination on renal function in salt loaded spontaneously hypertensive rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Body Weight; Calcium Channel Blockers; Creatinine; Hydrogen-Ion Concentration; Kidney; Kidney Function Tests; Male; Proteinuria; Rats; Rats, Inbred SHR; Sodium Chloride, Dietary; Urine; Valsartan | 2015 |
Effects of Renin-Angiotensin System Inhibitors on Renal Expression of Renalase in Sprague-Dawley Rats Fed With High Salt Diet.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Diet; Enalapril; Hydralazine; Kidney; Male; Monoamine Oxidase; Proteinuria; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Renin; Renin-Angiotensin System; Sodium Chloride, Dietary; Valsartan | 2015 |
Very high doses of valsartan provide renoprotection independently of blood pressure in a type 2 diabetic nephropathy rat model.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Hypertension; Linear Models; Male; Proteinuria; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Tetrazoles; Valine; Valsartan | 2009 |
Renoprotective efficacy of valsartan in chronic non-diabetic proteinuric nephropathies with renin-angiotensin system gene polymorphisms.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Chronic Disease; Female; Genotype; Humans; Kidney; Male; Middle Aged; Peptidyl-Dipeptidase A; Polymorphism, Genetic; Prospective Studies; Protective Agents; Proteinuria; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Tetrazoles; Transforming Growth Factor beta1; Valine; Valsartan | 2011 |
Valsartan inhibited HIF-1α pathway and attenuated renal interstitial fibrosis in streptozotocin-diabetic rats.
Topics: Animals; Blood Glucose; Blotting, Western; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Endothelin-1; Gene Expression; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Kidney; Male; Nephritis, Interstitial; Proteinuria; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Streptozocin; Tetrazoles; Tissue Inhibitor of Metalloproteinase-1; Valine; Valsartan | 2012 |
Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biomarkers; Blood Glucose; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dihydropyridines; Disease Progression; Drug Therapy, Combination; Glomerulonephritis; Glucagon; Glucose Transporter Type 1; Glycated Hemoglobin; Glycogen; Hypertension; Kidney; Male; Norepinephrine; Proteinuria; Rats; Rats, Inbred SHR; Renin-Angiotensin System; Tetrazoles; Transforming Growth Factor beta1; Valine; Valsartan | 2013 |
Targeting reduction of proteinuria in glomerulonephritis: Maximizing the antifibrotic effect of valsartan by protecting podocytes.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Dose-Response Relationship, Drug; Fibrosis; Glomerulonephritis; Intracellular Signaling Peptides and Proteins; Kidney; Kidney Function Tests; Male; Membrane Proteins; Podocytes; Proteinuria; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2014 |
Effect of angiotensin II antagonism on the regression of kidney disease in the rat.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Body Weight; Collagen Type III; Disease Progression; Kidney Diseases; Kidney Glomerulus; Lisinopril; Macrophages; Male; Monocytes; Proteinuria; Rats; Rats, Wistar; Renal Circulation; Tetrazoles; Valine; Valsartan | 2002 |
Role of angiotensin II and reactive oxygen species in cyclosporine A-dependent hypertension.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antioxidants; Blood Pressure; Creatinine; Cyclic N-Oxides; Cyclosporine; Hypertension; Immunosuppressive Agents; Male; Proteinuria; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Spin Labels; Tetrazoles; Valine; Valsartan | 2003 |
Effect of valsartan on urinary protein excretion and renal function in patients with chronic renal allograft nephropathy.
Topics: Adult; Aged; Antihypertensive Agents; Creatinine; Female; Glomerular Filtration Rate; Humans; Kidney Function Tests; Kidney Transplantation; Male; Middle Aged; Postoperative Complications; Potassium; Proteinuria; Tetrazoles; Time Factors; Valine; Valsartan | 2003 |
Anti-inflammatory effects of AT1 receptor blockade provide end-organ protection in stroke-prone rats independently from blood pressure fall.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents; Blood Pressure; Body Weight; Brain; Chemokine CCL2; Immunohistochemistry; Interleukin-1; Kidney; Magnetic Resonance Imaging; Male; Proteinuria; Rats; Rats, Inbred SHR; RNA, Messenger; Stroke; Survival Analysis; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan | 2004 |
[Angiotensin type 1 receptor blocker reduced proteinuria in patients of focal glomerular sclerosis].
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diet, Protein-Restricted; Drug Therapy, Combination; Glomerulosclerosis, Focal Segmental; Humans; Immunosuppressive Agents; Losartan; Male; Methylprednisolone; Middle Aged; Prednisolone; Proteinuria; Remission Induction; Ribonucleosides; Tetrazoles; Valine; Valsartan | 2004 |
Valsartan inhibited the accumulation of dendritic cells in rat fibrotic renal tissue.
Topics: Angiotensin II Type 2 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Dendritic Cells; Disease Models, Animal; Disease Progression; Fibrosis; Immunohistochemistry; Kidney Diseases; Kidney Function Tests; Kidney Tubules; Membrane Glycoproteins; Proteinuria; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2006 |
[Valsartan: arguments for the high dose concept].
Topics: Angiotensin II Type 1 Receptor Blockers; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Humans; Hypertension, Renal; Proteinuria; Tetrazoles; Valine; Valsartan | 2006 |
[Effects of benazepril and valsartan alone or in combination on proteinuria in chronic glomerular disease].
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Chronic Disease; Drug Therapy, Combination; Female; Glomerulonephritis; Humans; Male; Middle Aged; Proteinuria; Tetrazoles; Valine; Valsartan; Young Adult | 2007 |
Protective effects of valsartan and benazeprilat in salt-loaded stroke-prone spontaneously hypertensive rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Blood Pressure; Cerebrovascular Disorders; Genetic Predisposition to Disease; Heart Rate; Hypertension; Infusion Pumps; Kidney; Myocardium; Proteinuria; Rats; Rats, Inbred SHR; Renin; Renin-Angiotensin System; Sodium Chloride; Tetrazoles; Valine; Valsartan | 1998 |